| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
enVVeno Medical Corp
13D/A
Amendment 1
NVNO · 29415J205
|
0% |
9/15/2026
Event 9/11/2026
|
|||
| Braeden Lichti | 0% | ||||
| Northstrive Fund II LP | 0% | ||||
|
PMGC Holdings Inc.
13D/A
Amendment 1
ELAB · 73017P508
|
7.4% |
6/3/2026
Event 6/1/2026
|
|||
| Braeden Lichti | 7.4% | ||||
| Northstrive Companies Inc. | 7.4% | ||||
|
Bluejay Diagnostics, Inc.
13D/A
Amendment 1
BJDX · 095633608
|
0% |
6/2/2026
Event 6/2/2026
|
|||
| Braeden Lichti | 0% | ||||
| Northstrive Fund II LP | 0% | ||||
|
Bluejay Diagnostics, Inc.
13D
BJDX · 095633608
|
3.7% |
3/11/2026
Event 3/11/2026
|
|||
| Braeden Lichti | 3.7% | ||||
| Northstrive Fund II LP | 1.1% | ||||
|
enVVeno Medical Corp
13D
NVNO · 29415J205
|
5.1% |
2/20/2026
Event 2/20/2026
|
|||
| Braeden Lichti | 5.1% | ||||
| Northstrive Fund II LP | 3.1% | ||||
|
enVVeno Medical Corporation
13G
NVNO · 29415J205
|
5.1% |
2/10/2026
Event 2/10/2026
|
|||
| Braeden Lichti | 5.1% | ||||
| Northstrive Fund II LP | 3.1% | ||||
|
Bluejay Diagnostics, Inc.
13G
BJDX · 095633608
|
5.0% |
2/5/2026
Event 2/5/2026
|
|||
| Braeden Lichti | 5.0% | ||||
| Northstrive Fund II LP | 1.6% | ||||
|
Enveric Biosciences, Inc.
13G/A
Amendment 1
ENVB · 29405E505
|
0% |
12/10/2025
Event 12/9/2025
|
|||
| Braeden Lichti | 0% | ||||
| Northstrive Fund II LP | 0% | ||||
|
Enveric Biosciences, Inc.
13G
ENVB · 29405E505
|
5.0% |
12/5/2025
Event 12/3/2025
|
|||
| Braeden Lichti | 5.0% | ||||
| Northstrive Fund II LP | 4.3% | ||||
|
PMGC Holdings Inc.
13D
28622K302
|
52.4% |
3/28/2025
Event 3/26/2025
|
|||
|
PMGC Holdings Inc.
13D/A
Amendment 1
ELAB · 73017P201
|
0.2% |
3/28/2025
Event 9/24/2024
|
|||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.